Skip to main content
メニュー
Revvity logo
Contact us

Loading...

JP
Search all

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Blog
  • Small Molecule Drug Discovery
  • Antidepressant shows potential for treating COVID-19.
antidepressant1920

Blog

Small Molecule Drug Discovery

Jun 7th 2024

2 min read

Antidepressant shows potential for treating COVID-19.

Help us improve your Revvity blog experience!

Feedback


The speed at which researchers developed effective vaccines to prevent the spread of COVID-19 required unprecedented international cooperation on a scale never seen before. Rollout of approved vaccines is underway in many countries across the globe, giving people hope that the end to the pandemic is finally in sight.

Meanwhile, researchers are continuing to investigate possible treatments for patients suffering with the disease. In October last year, remdesivir was the first drug approved by the FDA for treating the SARS-CoV-2 virus. Remdesivir was originally developed to treat hepatitis C and was subsequently investigated for Ebola virus disease and Marburg virus infections before being studied as a post-infection treatment for COVID-19.

Many researchers are now looking at repurposing other existing drugs that might help fight the virus or reduce the immune reaction that occurs in COVID-19 patients. Drug repurposing has numerous advantages over conventional drug discovery, including reduced R&D costs and development timelines, as these drugs have already been tested for safety in humans.

A team of researchers from the Julius-Maximilians-Universität Würzburg in Germany decided to follow a similar path by screening approved medications against SARS-CoV-2.1 Specifically, they investigated the effect of the serotonin reuptake receptor inhibitors (SRRIs), fluoxetine, escitalopram, and paroxetine, which are usually used to treat depression, on viral replication.

To measure cytotoxicity and viral replication rates of a patient-derived virus isolate, the researchers first incubated cells with increasing concentrations of the compounds and subsequently infected them with SARS-CoV-2. Cell growth was determined using a Revvity EnSight® multimode plate reader. After three days, viral replication supernatants were collected, and viral RNA was extracted. Viral replication was quantified by real-time RTqPCR.

The researchers report that fluoxetine significantly inhibited SARS-CoV-2 at a concentration of 0.8 µg/ml. To test the specificity of the drug, the team also tested it against other viruses and found that it inhibited neither Rabies virus, human respiratory syncytial virus (RSV) replication, nor the Human Herpesvirus 8 or Herpes simplex virus type 1 gene expression, indicating that its action is virus-specific.

“Fluoxetine was introduced in clinics during the seventies and is a well-studied drug since it has been used in humans for almost four decades,” noted the team in the journal Scientific Reports. “Furthermore, the patent of Fluoxetine has long expired. Thus, it is available from different companies, and relatively cheap. We see the role of Fluoxetine in the early treatment of SARS-CoV-2 infected patients of risk groups.”

For research use only. Not for use in diagnostic procedures.

Revvity, Inc. does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.  

References:
  1. Zimniak, M., Kirschner, L., Hilpert, H. et al. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep 11, 5890 (2021). https://doi.org/10.1038/s41598-021-85049-0 
     

Help us improve your Revvity blog experience!

Feedback

Share this post:

  • Email
  • Facebook
  • Linkedin
  • Twitter

続き Small Molecule Drug Discovery posts

Microfluidic electrophoresis for nucleic acid and protein analysis.
Read
Optimizing assay duration in cell panel screens for slow-acting therapeutics.
Read
Top tips for getting started with antibody validation using cell lines.
Read

Questions?
We’re here to help.

Contact us
Revvity Logo

Loading...

    ©2025 Revvity - All rights reserved

    Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.